Rome, Italy

Antonio Sella

This inventor holds 1 USPTO granted patent. Top assignee: Other. Active years: 2002.


% Patents Active = 100.0

Average Co-Inventor Count = 14.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:

goldMedal1 out of 834,350 
Other
 patents

Years Active: 2002

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Antonio Sella: Innovator in Metalloproteinase Inhibitors

Introduction

Antonio Sella is a notable inventor based in Rome, Italy. He has made significant contributions to the field of biochemistry, particularly in the development of metalloproteinase inhibitors. His work focuses on the therapeutic applications of these compounds, which are crucial in various medical treatments.

Latest Patents

Antonio Sella holds a patent titled "Metalloproteinase inhibitors, their therapeutic use and process for the production of the starting compound in the synthesis thereof." This patent highlights his innovative approach to creating effective inhibitors that can be utilized in therapeutic settings. He has 1 patent to his name, showcasing his expertise in this specialized area.

Career Highlights

Throughout his career, Antonio has demonstrated a commitment to advancing scientific knowledge and improving therapeutic options. His research has been instrumental in understanding the role of metalloproteinases in various diseases, paving the way for new treatment methodologies.

Collaborations

Antonio has collaborated with esteemed colleagues, including Cinzia Piazza and Enrico Gavuzzo. These partnerships have enriched his research and contributed to the successful development of his patented innovations.

Conclusion

Antonio Sella is a distinguished inventor whose work in metalloproteinase inhibitors has the potential to impact therapeutic practices significantly. His contributions to the field reflect a dedication to innovation and scientific advancement.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…